Zogenix drug cuts seizure rate in severe epilepsy, sending stock skyrocketing

Zogenix (ZGNX) closed out September’s crammed clinical trial calendar with an impressive win.

The small biotech company, based in Emeryville, Calif., said its lead drug, ZX008, significantly reduced seizure activity compared to a placebo in children with Dravet syndrome, a rare and severe type of epilepsy.

The positive results from the phase 3 clinical trial means Zogenix is halfway towards its goal of filing an FDA marketing application in the second half of 2018. The company is waiting on results from a second phase 3 study of ZX008, expected to read out in the first half of 2018.


Investors were not waiting to celebrate, sending Zogenix shares skyrocketing by 184 percent to $36.50 in Friday’s pre-market session.

ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. You might remember fenfluramine

... read more at: https://www.statnews.com/2017/09/29/zogenix-drug-cuts-seizure-rate-severe-epilepsy-patients-stock-price-skyrockets/